Garadacimab provides early onset of protection against HAE attacks from Week 1 after first administration

000548

M. Magerl,[1–3] A. Reshef,[4] P. Staubach,[5] M. Guilarte,[6] P. Li,[7] C. Nenci,[8] F. Glassman,[9] I. Pragst,[8] J-P. Lawo,[8] T. Craig[10]

[1]Institute of Allergology, Charité–Universitätsmedizin Berlin, Berlin, Germany; [2]Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; [3]Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany; [4]Allergy, Immunology and Angioedema Center, Barzilai University Hospital, Ashkelon, Israel; [5]Department of Dermatology and Allergy, University Medical Center Mainz, Mainz, Germany; [6]Allergy Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain; [7]Division of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong; [8]CSL Behring AG, Bern, Switzerland; [9]CSL Behring, King of Prussia, PA, USA; [10]Allergy, Asthma and Immunology, Department of Medicine and Pediatrics, Penn State University, Hershey, PA, USA.

BACKGROUND

- Early onset of efficacy and durable attack protection are critical to optimize disease control and establish treatment confidence
- Garadacimab is a first-in-class, fully human mAb targeting FXIIa under evaluation for HAE in pediatric, adolescent, and adult patients[1–3]

STUDY DESIGN AND KEY OUTCOMES OF THE PIVOTAL PHASE 3 AND OLE STUDIES

87% **Reduction** in mean monthly number of HAE attacks vs placebo in pivotal **Phase 3 (VANGUARD) study**, P<0.0001 (median reduction **100%**; exposure 6 months)[2]

95% **Reduction** in mean monthly number of HAE attacks vs run-in in **Phase 3 OLE** (median reduction **100%**; exposure 13.8 months)[4]

Favorable long-term safety and tolerability profiles in both Phase 3 studies[2,4]

Eligibility[2,4]

- **HAE diagnosis**
- **Aged ≥12 years**
- **Baseline ≥1 attack/month**



***Post hoc* analysis from the pivotal and OLE Phase 3 studies**

Early onset of efficacy and durable protection from HAE attacks demonstrated by garadacimab

GARADACIMAB SHOWS EARLY ONSET AND DURABLE PROTECTION FROM HAE ATTACKS



Garadacimab reduced mean monthly attack number as early as Week 1 vs run-in, compared to placebo



Garadacimab reduced mean monthly attack number as early as Week 1 vs run-in

GARADACIMAB CONCENTRATION EXCEEDS THERAPEUTIC THRESHOLD AFTER FIRST ADMINISTRATION



- $C_{min,ss}$ of 6 µg/mL identified as target threshold corresponding to ≥90% relative risk reduction in HAE attacks as determined by exposure-response analysis[5]

Garadacimab exposure exceeded target therapeutic threshold of 6 µg/mL after the first administration and remained over threshold through to Day 30‡

CONCLUSIONS

- Early onset of protection from HAE attacks with garadacimab as early as Week 1 after first administration in both pivotal and OLE Phase 3 studies
- Durable protection from HAE attacks with garadacimab across 15 months in the Phase 3 OLE study
- Garadacimab exposure exceeded target therapeutic threshold from Week 1 after first administration

*One patient in the placebo arm was excluded from efficacy analysis as they received treatment for <30 days; †TEAEs in patients with HAE-C1-INH; ‡Pharmacokinetic parameters were evaluated after the initial loading dose in a representative subset of newly enrolled patients (n=15).
CI, confidence interval; $C_{min,ss}$, minimum concentration in the dosing interval at steady state; FXIIa, activated factor XII; HAE, hereditary angioedema; HAE-C1-INH, hereditary angioedema with C1-inhibitor deficiency or dysfunction; M, month; mAb, monoclonal antibody; OLE, open-label extension; q1m, once-monthly; SC, subcutaneous; SD, standard deviation; TEAE, treatment-emergent adverse event; W, week.

References

1. Cao H et al. *J Allergy Clin Immunol* 2018;142:1355–1358; 2. Craig TJ et al. *Lancet* 2023;401:1079–1090; 3. ClinicalTrials.gov. NCT05819775. Available at: https://clinicaltrials.gov/ct2/show/NCT05819775 (accessed May 2024); 4. Anderson J et al. Abstract A016. Presented at the American College of Allergy, Asthma & Immunology 2023 Annual Scientific Meeting, November 9–13, 2023, Anaheim, California; 5. Sharma A et al. Poster PII-142. 2024. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, March 27–29, 2024, Colorado Springs, CO, USA.

Disclosures

This study was sponsored by CSL Behring. Medical writing support was provided by Helix, OPEN Health Communications, and funded by CSL Behring, in accordance with Good Publication Practice (GPP) guidelines (www.ismpp.org/gpp-2022).

European Academy of Allergy and Clinical Immunology Congress | Valencia, Spain | May 31 – June 3, 2024

Scan the QR code to access the poster